Navigation Links
Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease
Date:10/8/2008

e future. Neither can there be any guarantee regarding the long-term impact of a patient's use of Gleevec. In particular, management's expectations regarding Gleevec could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical trial data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets leading innovative prescription drugs used to treat a number of diseases and conditions, including those in the cardiovascular, metabolic, cancer, organ transplantation, central nervous system, dermatological, GI and respiratory areas. The company's mission is to improve people's lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG (NYSE:

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test
2. Physicians Estimate That if Approved, Ceftobiprole Will Steal Nearly a Third of Zyvoxs Patient Share in the Treatment of Nosocomial Pneumonia
3. Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS
4. New Data Presented at WCTRIMS* Supports the Importance of Early and Sustained Treatment with Betaseron(R)
5. Electronic Brachytherapy a Viable Option for Early Stage Breast Cancer, According to Study Presented at ASCO Breast Cancer Symposium
6. K-State Researchers Awarded Nearly $1 Million to Test Remedies, Investigate Link Between E. Coli and Distillers Grains
7. Markers in Blood and Spinal Fluid, and a New Imaging Agent, Show Promise for Early Detection of Alzheimers
8. Snapshots of Eyes Could Serve as Early Warning of Diabetes or Diabetic Eye Disease, U-M Researchers Report
9. Eight-Year Melanoma Remission is Among Early Cancer Treatment Results
10. Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients Day
11. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), a specialty ... innovative therapies for the treatment of acute pain, today ... the three and six months ended June 30, 2015. ... 23, 2015, the Committee for Medicinal Products for Human ... the management of acute moderate-to-severe post-operative pain in adult ...
(Date:8/3/2015)... Aug. 3, 2015 Diplomat Pharmacy, Inc. (NYSE: ... results for the quarter ended June 30, 2015. All comparisons, ... 2014. Second Quarter 2015 Highlights include: ... or $266 million , Total prescriptions dispensed of 234,000, ... versus 5.5% , Adjusted EBITDA of $22.7 million, an ...
(Date:8/3/2015)... , Aug. 3, 2015  LEO Pharma supports ... Administration (FDA) to include psoriasis as one of eight ... Development Initiative i .  Psoriasis is an autoimmune disease ... subsequent comorbidities, affecting 7.5 million people in the US ... Pharma,s ongoing commitment to supporting patients living with psoriasis, ...
Breaking Medicine Technology:AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 3AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 4AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 5AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 6AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 7AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 8AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 9AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 2Diplomat Announces 2nd Quarter 2015 Financial Results 3Diplomat Announces 2nd Quarter 2015 Financial Results 4Diplomat Announces 2nd Quarter 2015 Financial Results 5Diplomat Announces 2nd Quarter 2015 Financial Results 6Diplomat Announces 2nd Quarter 2015 Financial Results 7Diplomat Announces 2nd Quarter 2015 Financial Results 8Diplomat Announces 2nd Quarter 2015 Financial Results 9Diplomat Announces 2nd Quarter 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 11Diplomat Announces 2nd Quarter 2015 Financial Results 12Diplomat Announces 2nd Quarter 2015 Financial Results 13Diplomat Announces 2nd Quarter 2015 Financial Results 14Diplomat Announces 2nd Quarter 2015 Financial Results 15Diplomat Announces 2nd Quarter 2015 Financial Results 16Diplomat Announces 2nd Quarter 2015 Financial Results 17Diplomat Announces 2nd Quarter 2015 Financial Results 18LEO Pharma Supports the FDA's Selection of Psoriasis as a Priority Disease 2LEO Pharma Supports the FDA's Selection of Psoriasis as a Priority Disease 3
... ALLEGAN, Mich. , Jan. 27 Perrigo ... declared a quarterly dividend of $0.0625 per share, ... record on February 26, 2010 . , Perrigo Company ... distributes over-the-counter (OTC) and generic prescription pharmaceuticals, nutritional products, active ...
... , , , , RALEIGH, ... leading Clinical Research Organization, announces it has entered into a ... company, and its exclusive partner IBPC, a non-profit oncology research ... which collectively treat an estimated 140,000 new incidences of cancer ...
Cached Medicine Technology:PRA International Formalizes Partnership with Oncopartners and IBPC 2PRA International Formalizes Partnership with Oncopartners and IBPC 3PRA International Formalizes Partnership with Oncopartners and IBPC 4PRA International Formalizes Partnership with Oncopartners and IBPC 5
(Date:8/4/2015)... Hanover, MA (PRWEB) , ... August 04, 2015 , ... ... Brain Aneurysm Awareness on Sunday, September 20th at Oneida Shores Park in Brewerton, ... after suffering from a ruptured brain aneurysm at the young age of 59. Her ...
(Date:8/4/2015)... ... August 04, 2015 , ... IN AMERICA and the ... treating depression. Depression affects millions of Americans every single year. To help people ... enlighten viewers with the latest segment produced with the assistance of several top ...
(Date:8/4/2015)... DC (PRWEB) , ... August 04, 2015 , ... Following ... two new videos: The Benefits of Cath Lab Accreditation in an Academic Setting, and ... in an Academic Setting , taped during the 2015 Society for Cardiovascular Angiography ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... make the Isabel Symptom Checker available to all users of the KHIN personal ... check their symptoms in an easy, intuitive method, provides access to material on ...
(Date:8/3/2015)... ... 04, 2015 , ... While the pace of the economic recovery since the 2008 has been ... a growth trajectory for the last six years. Unemployment has dropped from a 2009 high ... 3.5 percent growth rate in 2014, the U.S. stock market is at an all time ...
Breaking Medicine News(10 mins):Health News:4th Annual Doris A. Connor Memorial Event for Brain Aneurysm Awareness to be Held in Brewerton, NY with Proceeds Benefitting Renowned Brain Aneurysm Foundation 2Health News:4th Annual Doris A. Connor Memorial Event for Brain Aneurysm Awareness to be Held in Brewerton, NY with Proceeds Benefitting Renowned Brain Aneurysm Foundation 3Health News:Accreditation for Cardiovascular Excellence (ACE) Clients Explain Benefits of ACE Accreditation 2Health News:Accreditation for Cardiovascular Excellence (ACE) Clients Explain Benefits of ACE Accreditation 3Health News:Isabel Healthcare Partners with the Kansas Health Information Network, Inc. to Deploy Isabel Symptom Checker within the MyKSHealth eRecord Personal Health Record 2Health News:Isabel Healthcare Partners with the Kansas Health Information Network, Inc. to Deploy Isabel Symptom Checker within the MyKSHealth eRecord Personal Health Record 3Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 2Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 3Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 4
... -- A University of Michigan Health System laboratory study reveals ... could lead to a new treatment for those with sickle ... in this week,s early edition of the Proceedings of ... preventing the painful episodes and organ damage that are common ...
... Gordon HealthDay Reporter , TUESDAY, Nov. 1 (HealthDay ... their risk of developing cancer compared to the general population. ... cancer, according to new research. In any ... transplant is just 0.7 percent. And experts say the benefits ...
... Gardner HealthDay Reporter , TUESDAY, Nov. 1 ... disorder don,t appear to raise the risk of heart ... adults, new research shows. And if any ... Concerta does exist, the danger in absolute numbers would ...
... equation that is difficult to solve for most people, but ... transport can be an almost insurmountable task. A newly launched ... now enlisting the help of the senior citizens themselves to ... hoped that the results will lead to better urban planning. ...
... -- Women undergoing angioplasty, a procedure to unblock a clogged ... to new research. However, the study also shows ... an angioplasty than male patients. In conducting the study, ... Interventions , researchers analyzed information on almost 4,800 women and ...
... from Rhode Island Hospital examined how the perception of ... Through a web survey with embedded interventions, the researchers ... indicators of patient satisfaction, while staff reported changing or ... paper was published in the European Journal of ...
Cached Medicine News:Health News:Researchers reveal potential treatment for sickle cell disease 2Health News:Cancer Risk Doubles After Organ Transplant, Study Finds 2Health News:Cancer Risk Doubles After Organ Transplant, Study Finds 3Health News:Little Evidence of Heart Risks From ADHD Meds 2Health News:Little Evidence of Heart Risks From ADHD Meds 3Health News:Little Evidence of Heart Risks From ADHD Meds 4Health News:Senior citizens as co-researchers to improve urban planning 2Health News:Women No More Likely to Die After Angioplasty 2Health News:How staff perceptions of their roles impact patients experience in the emergency department 2Health News:How staff perceptions of their roles impact patients experience in the emergency department 3
... was developed to address hematology needs ... of use, low maintenance, closed-tube sampling, ... are features expected in the modern ... fast access to results, sophisticated data ...
Inquire...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: